Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346271 | 0.81 | CYP2C19 (0.36) | KDM4EALDH1A1LMNAALOX15BLM | |
| SCHEMBL18520328 | 0.78 | HIF1A (0.39) | KDM4EMAPK1HIF1APAOXTSHR | |
| Hydrochloric Acid SCHEMBL1097195 | 0.77 | NOS1 (0.31) | KDM4EALDH1A1LMNAALOX15BLM | |
| SCHEMBL8466979 | 0.76 | CYP2D6 (0.33) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6386792 | 0.75 | — | — | |
| SCHEMBL787861 | 0.75 | — | — | |
| SCHEMBL15726863 | 0.75 | — | — | |
| SCHEMBL19851260 | 0.75 | — | — | |
| SCHEMBL5509686 | 0.74 | MAOA (0.47) | KDM4ETSHRALDH1A1LMNATDP1 | |
| SCHEMBL73996 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703976-B2 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | MILAN SOUKUP (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703976-B2 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | MILAN SOUKUP (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120296100-A1 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | CarboDesign LLC (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296100-A1 | Manufacturing process for 8-aryloctanoic acids such as Aliskiren | BCKDK, ACSL6, KHK | KDM4E 670/4885MAPK1 1728/4885HIF1A 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.